UK-based pharmaceutical firm AstraZeneca denied recent reports that the company was in talks to possible be acquired by US rival Pfizer, a deal experts valued at $101 billion – one of the largest-ever for the industry.
According to one source, Pfizer had made numerous informal merger advances to the UK firm. Reports placed one of those offers at about $101 billion, a deal that would surpass Pfizer’s largest buyout to date, its $90 billion acquisition of Warner-Lambert.
While earlier reports noted that AstraZeneca had dismissed the buyout offers, some experts predict a potential deal could emerge in the future. But additional sources say the companies are not in merger talks as of now.
Meanwhile, reports say Pfizer has agreed to settle a class action pay-for-delay lawsuit with a $190 million offer.
According to court documents filed Monday, the company was accused of paying the generic maker of its epilepsy drug Neurontin to keep the cheaper competitor off pharmaceutical shelves, an agreement known as pay-for-delay.
The lawsuit was filed in 2002.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI